Literature DB >> 18208498

Hepatitis C in ethnic minority populations in England.

A G Mann1, C L Trotter, M Adekoyejo Balogun, M E Ramsay.   

Abstract

The aim of the study was to investigate the differing epidemiology of hepatitis C-related end-stage liver disease in ethnic minorities in England. We used Hospital Episode Statistics from 1997/98 to 2004/05 to directly age-standardize numbers of episodes and deaths from hepatitis C-related end-stage liver disease in ethnic groups using the white English population as standard and the age-structured population by ethnic group from the 2001 Census. We estimated the odds of having a diagnosis of end-stage liver disease amongst hepatitis C-infected individuals in each ethnic group compared with whites using logistic regression. The main outcome measures were age-standardized morbidity and mortality ratios and morbidity and mortality odds ratios. Standardized ratios (95% confidence interval) for hepatitis C-related end-stage liver disease ranged from 73 (38-140) in Chinese people to 1063 (952-1186) for those from an 'Other' ethnic group. Amongst individuals with a diagnosis of hepatitis C infection, the odds ratios (95% CI) of severe liver disease were 1.42 (1.13-1.79), 1.57 (1.36-1.81), 2.44 (1.85-3.22), 1.73 (1.36-2.19) and 1.83 (1.08-3.10) comparing individuals of Black African, Pakistani, Bangladeshi, Indian and Chinese origin with whites, respectively. Ethnic minority populations in England are more likely than whites to experience an admission or to die from severe liver disease as a result of hepatitis C infection. Ethnic minority populations may have a higher prevalence of hepatitis C or they may experience a poorer prognosis because of differential access to health services, longer duration of infection or the prevalence of co-morbidities.

Entities:  

Mesh:

Year:  2008        PMID: 18208498     DOI: 10.1111/j.1365-2893.2007.00958.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

1.  What do primary care staff know and do about blood borne virus testing and care for migrant patients? A national survey.

Authors:  Rachel Roche; Ruth Simmons; Alison F Crawshaw; Pip Fisher; Manish Pareek; Will Morton; Theresa Shryane; Kristina Poole; Arpana Verma; Ines Campos-Matos; Sema Mandal
Journal:  BMC Public Health       Date:  2021-02-11       Impact factor: 3.295

Review 2.  Chronic hepatitis C: Diagnosis and treatment made easy.

Authors:  Naim Abu-Freha; Binil Mathew Jacob; Ali Elhoashla; Zaid Afawi; Talab Abu-Hammad; Foad Elsana; Sergey Paz; Ohad Etzion
Journal:  Eur J Gen Pract       Date:  2022-12       Impact factor: 3.636

3.  Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations.

Authors:  Nimzing G Ladep; Shahid A Khan; Mary Me Crossey; Andrew V Thillainayagam; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 4.  Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review.

Authors:  John A Owiti; Trisha Greenhalgh; Lorna Sweeney; Graham R Foster; Kamaldeep S Bhui
Journal:  BMC Public Health       Date:  2015-02-15       Impact factor: 3.295

5.  Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals.

Authors:  Lorna Sweeney; John A Owiti; Andrew Beharry; Kamaldeep Bhui; Jessica Gomes; Graham R Foster; Trisha Greenhalgh
Journal:  BMC Health Serv Res       Date:  2015-03-13       Impact factor: 2.655

6.  Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC).

Authors:  Patricia C Valery; Christina M Bernardes; Katherine A Stuart; Gunter F Hartel; Steven M McPhail; Richard Skoien; Tony Rahman; Paul J Clark; Leigh U Horsfall; Kelly L Hayward; Rohit Gupta; Elizabeth E Powell
Journal:  Patient Prefer Adherence       Date:  2020-03-18       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.